UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock

robot
Abstract generation in progress

UBS Group has raised its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $8.00 from $7.00, maintaining a “buy” rating and suggesting a significant upside. Despite weak fundamentals, the company shows positive clinical progress with promising data for its [212Pb]VMT‑α‑NET therapy. Institutional investors have also been adjusting their holdings in the company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments